Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
863.2 DKK | -0.02% | -4.11% | +11.89% |
02-27 | Certain B Shares of Coloplast A/S are subject to a Lock-Up Agreement Ending on 27-FEB-2024. | CI |
02-14 | COLOPLAST : Q1 24: Many more positives beyond the margin beat |
Summary
- According to Refinitiv, the company's ESG score for its industry is good.
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- Considering the small differences between the analysts' various estimates, the group's business visibility is good.
Weaknesses
- The group shows a rather high level of debt in proportion to its EBITDA.
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 36.19 times its estimated earnings per share for the ongoing year.
- Based on current prices, the company has particularly high valuation levels.
- The company appears highly valued given the size of its balance sheet.
- The company is highly valued given the cash flows generated by its activity.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+11.89% | 27.79B | B+ | ||
-31.67% | 2.98B | B- | ||
-15.97% | 2.52B | C+ | ||
+11.90% | 2.34B | - | A- | |
-1.11% | 1.91B | B | ||
-7.78% | 1.39B | B | ||
-0.38% | 1.27B | - | ||
+3.58% | 1.13B | - | ||
+13.51% | 1.12B | C | ||
-0.81% | 1.02B | B |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- COLO B Stock
- Ratings Coloplast A/S